Co-promotion of sales and medical affairs percentage.

No definition available.

Name:	mdvn_CoPromotionOfSalesAndMedicalAffairsPercentage
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Deferred revenue additions related to development milestones.

+ References

No definition available.

+ Details

Name:	mdvn_DeferredRevenueAdditionsRelatedToDevelopmentMilestones
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Eligible future milestone payments under collaboration arrangement.

+ References

No definition available.

+ Details

Name:	mdvn_EligibleFutureMilestonePaymentsUnderCollaborationArrangement
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Percentage Of Sales Milestone Payments

+ References

No definition available.

+ Details

Name:	mdvn_PercentageOfSalesMilestonePayments
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage Of Up Front And Development Cash Payments To Licensor

+ References

No definition available.

+ Details

Name:	mdvn_PercentageOfUpFrontAndDevelopmentCashPaymentsToLicensor
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Share Percentage Of Development And Commercialization Cost Under Former Collaboration

+ References

No definition available.

+ Details

Name:	mdvn_SharePercentageOfDevelopmentAndCommercializationCostUnderFormerCollaboration
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Collaboration Agreements (Narrative) (Detail) (USD $) In Millions, unless otherwise specified	6 Months Ended	3 Months Ended			6 Months Ended	3 Months Ended	6 Months Ended	3 Months Ended		6 Months Ended	3 Months Ended
	Jun. 30, 2012	Dec. 31, 2008 Pfizer [Member] Collaborative Arrangement [Member]	Jun. 30, 2012 Up-front Payment Arrangement [Member] Astellas [Member]	Dec. 31, 2008 Up-front Payment Arrangement [Member] Pfizer [Member]	Jun. 30, 2012 Up-front Payment Arrangement [Member] Pfizer [Member]	Jun. 30, 2012 Development Milestone Payments [Member] Astellas [Member]	Jun. 30, 2012 Development Milestone Payments [Member] Astellas [Member]	Dec. 31, 2008 Development Milestone Payments [Member] Pfizer [Member] Collaborative Arrangement [Member]	Jun. 30, 2012 Sales Milestone Payments [Member] Astellas [Member]	Jun. 30, 2012 Sales Milestone Payments [Member] Astellas [Member]	Dec. 31, 2008 Commercial Milestone Payments [Member] Pfizer [Member] Collaborative Arrangement [Member]
Deferred Revenue Arrangement [Line Items]
Percentage of sales and medical affairs	50.00%
Non-refundable up-front cash payment		$ 225.0	$ 110.0	$ 225.0	$ 225.0		$ 123.0
Eligible to receive milestone payments						335.0			320.0	320.0
Deferred revenue additions related to development milestones							$ 13.0
Percentage of up-front cash payments to licensor							10.00%
Percentage of share as per ARN-509										10.00%
Share percentage of developing and commercializing dimebon								60.00%			40.00%